



## Design and development of a web-based registry for Coronavirus (COVID-19) disease

Hadi Kazemi-Arpanahi<sup>1</sup>, Khadijeh Moulaei<sup>2</sup>, Mostafa Shanbehzadeh\*<sup>3</sup>

Received: 15 Apr 2020

Published: 25 Jun 2020

### Abstract

**Background:** The 2019 coronavirus (COVID-19) is a highly contagious disease associated with a high morbidity and mortality worldwide. The accumulation of data through a prospective clinical registry enables public health authorities to make informed decisions based on real evidence obtained from surveillance of COVID-19. This registry is also fundamental to providing robust infrastructure for future research surveys. The purpose of this study was to design a registry and its minimum data set (MDS), as a valid and reliable data source for reporting and benchmarking COVID-19.

**Methods:** This cross sectional and descriptive study provides a template for the required MDS to be included in COVID-19 registry. This was done by an extensive literature review and 2 round Delphi survey to validate the content, which resulted in a web-based registry created by Visual Studio 2019 and a database designed by Structured Query Language (SQL).

**Results:** The MDS of COVID-19 registry was categorized into the administrative part with 3 sections, including 30 data elements, and the clinical part with 4 sections, including 26 data elements. Furthermore, a web-based registry with modular and layered architecture was designed based on final data classes and elements.

**Conclusion:** To the best of our knowledge, COVID-19 registry is the first designed instrument from information management perspectives in Iran and can become a homogenous and reliable infrastructure for collecting data on COVID-19. We hope this approach will facilitate epidemiological surveys and support policymakers to better plan for monitoring patients with COVID-19.

**Keywords:** Minimum data set, MDS, Registry system, COVID-19, Coronavirus

**Conflicts of Interest:** None declared

**Funding:** Ilam University of Medical Sciences

\*This work has been published under CC BY-NC-SA 1.0 license.

Copyright© Iran University of Medical Sciences

**Cite this article as:** Kazemi-Arpanahi H, Moulaei Kh, Shanbehzadeh M. Design and development of a web-based registry for Coronavirus (COVID-19) disease. *Med J Islam Repub Iran.* 2020 (25 Jun);34:68. <https://doi.org/10.47176/mjiri.34.68>

### Introduction

In December 2019, a series of cases of pneumonia with unknown etiology occurred in Wuhan, Hubei Province, China. On January 7, 2020, the novel coronavirus (COVID-19), previously known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV), was identified as the causative organism (1, 2). It is classified as a type of RNA virus that belongs to the family of coronaviruses, which primarily leads to a respiratory sys-

tem infection (3). COVID-19 is highly contagious that rapidly spread to other countries. The World Health Organization (WHO) has recently declared the COVID-19 a public health emergency (4).

Given the significant burdens associated with COVID-19, decision was made to adopt information technology and data infrastructures to bolster efficient research, surveillance, and treatment of this emerging outbreak. Clini-

**Corresponding author:** Dr Mostafa Shanbehzadeh, [shanbehzadeh-m@medilam.ac.ir](mailto:shanbehzadeh-m@medilam.ac.ir)

<sup>1</sup> Department of Health Information Technology, Abadan Faculty of Medical Sciences, Abadan, Iran

<sup>2</sup> Department of Health Information Management, School of Health Management and Information Sciences, Kerman University of Medical Sciences, Kerman, Iran

<sup>3</sup> Department of Health Information Technology, School of Paramedical, Ilam University of Medical Sciences, Ilam, Iran

#### ↑What is “already known” in this topic:

Disease registries are collections of secondary data related to patients with a specific diagnosis, condition, or procedure, and they play an important role in clinical and managerial decisions.

#### →What this article adds:

COVID-19 registry facilitates studying the real clinical practice, capturing quality metrics, monitoring the disease and healthcare delivery patterns, and tracing clinical outcomes.

cal registry is one of such information platforms that standardize the collection of highly generalizable data and reinforce research infrastructure (5, 6). Clinical registries have a great potential for epidemiological surveillance, evaluating health-care delivery patterns, tracking clinical outcomes, describing disease natural progression, evidence-based therapy, and comparing the effectiveness of different interventions and post marketing drug surveillance. Moreover, clinical registries allow the study of the designed parameters and recruitment of participants for clinical trials (7-10). The COVID-19 registry will serve as a data source to standardize collection of comprehensive data related to many unclear aspects of COVID-19, such as transmission patterns, severity, clinical phenotype, prognostic factors, therapeutics' plans effectiveness and complications, survival estimation, incidence and prevalence of disease across country, and thereby allowing collaboration on research and surveillance of COVID-19.

However, despite the advantages afforded by clinical registries, some considerations need to be addressed from a data management perspective: the design of an effective data capture system and determination of the required data elements and validity of their corresponding values (11-13). Therefore, in this study, the required data elements for COVID-19 were defined and a clinical registry platform that met these requirements was designed.

## Methods

This was a cross-sectional and descriptive study in 2020 that was conducted in two phases: in the first one, the aim was to identify required data elements and validated data capture template to be included in the COVID-19 registry, and the second one was designing a registry system for COVID-19 on the web platform.

### COVID-19 registry data element determination

#### Literature review

First, an extensive literature review to identify the COVID-19 MDS data elements was performed. In the first step to retrieve related resources, the Web of Science, ScienceDirect, Embase, Scopus, Elsevier, Cochran, PubMed and Google Scholar were reviewed, and the follow-

ing search terms were used: (designed using English MeSH keywords and Emtree terms): "COVID-19" or "Novel coronavirus 2019" or "2019 nCoV" and "clinical characteristics" or "para clinical characteristics" or "epidemiological characteristics". After selecting the advance search interface in the mentioned databases using title, title/abstract, title/abstract/keyword and topic fields, and setting up Boolean operators (AND, OR) and implementing the input and output criteria (full text English articles from Dec 2019- Mar 2020), 18 articles were included in the study (3, 14-30). Data were extracted from the related retrieved resources and entered into the checklist with 2 administrative and clinical sections.

#### Questionnaire development

A questionnaire was developed using the data elements of the checklist and included 5 columns: "very important", "important", "neutral", "low important", and "very important" for each data item (eg, patient name, visit number, vital sign, exposure and etc.). To add necessary data elements by experts, a blank row was provided at the end of the questionnaire. The content validity of the questionnaire was assessed by an expert panel, including 2 infectious specialists and 3 health information management (HIM) experts. Also, test-retest was used to evaluate the reliability of the questionnaire.

#### Delphi phase

The initial MDS content was validated by Delphi technique using 2 rounds by a group of multidisciplinary experts working in hospitals affiliated to Ilam University of Medical Sciences (west of Iran). Table 1 shows the demographic characteristics of these experts. The experts were asked to review the initial data list to score each item according to their importance perceived by them based on a 5-point Likert scale, ranging from 1 to 5, where 1 indicated "not important" for inclusion and 5 indicated "highly important" for inclusion.

Agreement was reached for data elements based on experts' agreement level. After initial ranking, items with less than 50% agreement were deleted, those with more than 75% agreement excluded from the second round, and those with 50% to 75% agreement were surveyed in the second round. The checklists were individually presented

Table 1. Demographic characteristics of Delphi participants

Variables	Frequency	Percentage
Specialty		
Infectious disease	9	39.12
Internal medicine	8	34.79
Radiologist	6	26.09
Gender		
Female	8	34.79
Male	15	65.21
Age (years)		
30-40	9	39.12
40-50	6	26.09
50-60	6	26.09
>60	2	8.7
Work experience (years)		
<10	6	26.09
10-20	11	47.82
20-30	5	21.74
>30	1	4.35
Total	23	100

to the experts who were blind to the scores of other experts, and if there was 75% consensus over a subject, it was included into the final MDS.

#### COVID-19 registry software development tools

We used Visual Studio 2019 to design COVID-19 web-based registry because of its numerous benefits (eg, cost-effectiveness, scalability and accessibility, user friendliness, fast and convenience, custom search, improved intelligence, clipboard and refactoring attributes) (31, 32). The proposed system was implemented with cascading style sheets (CSS) technology as a web-based program. CSS, along with the Hypertext Markup Language (HTML), was used to describe the presentation of documents and set the document syntax, layout, display format, and visual effects (eg, font type, color, spacing, and sizes). The code was written in Java script language for designing the website. Finally, Structured Query Language (SQL) was used to create the relational database (RDB). SQL provides efficient and systematic storage of data with high performance, availability, scalability, flexibility, management,

and security (33).

#### Results

The results of this study are divided into 3 phases:

##### Determining the proposed MDS for COVID-19

The proposed COVID-19 MDS was divided into the nonclinical section with 4 data classes, including 43 data elements, and the clinical data category with 4 data classes, including 44 data items. The nonclinical section includes sociodemographic, identification number, and patient disposition classes, and the clinical category includes diagnostic, exposure, physical examination, and medical / diagnostic procedure.

##### Determining final minimum data Set for COVID-19

The potential participants who determined the final data elements of the MDS of the COVID-19 registry were 25 medical specialists. However, 2 specialists did not participate in the study. Table 1 shows the demographic characteristics of the experts. The results of the 2 Delphi rounds

Table 2. Examples of nonclinical and clinical data classes for COVID-19 MDS

Data classes	Total number of elements	First round of Delphi			Second round of Delphi			Final
		< 50%	50-75%	75% <	< 50%	50-75%	75% <	
Administrative data category								
Sociodemographic characteristics	18	3	10	5	1	0	4	14
Identification	10	3	4	3	3	0	1	4
Patient disposition	15	2	10	3	1	0	2	12
Clinical data category								
Diagnostic	15	3	9	3	2	0	1	10
Exposure	8	3	2	3	2	0	1	3
Physical examination	11	3	4	4	2	0	2	6
Medical procedures	10	1	6	3	2	0	1	7
Total	87	18	45	24	12	0	12	56

Table 3. Weighting of data items after the second round of Delphi

Data classes	No	Data elements	Mean	Percentage	Final decision
Sociodemographic	1	Patient's name	4.1	82	Kept
	2	Father's name	3.85	77	Kept
	3	Spouse / partner's name	2.1	42	Removed
	4	Age (in years)	4.15	83	Kept
	5	Sex	4.5	90	Kept
	6	Date of birth	3.95	79	Kept
	7	Place of birth	4.25	85	Kept
	8	Marital status	4.09	81.8	Kept
	9	Income	2.3	46	Removed
	10	Religion	2.5	50	Removed
	11	Employment status	3.95	79	Kept
	12	Occupation	4.01	80.2	Kept
	13	Educational level	4.12	82.4	Kept
	14	Race/ nationality	3.55	77	Kept
	15	Home address	4.05	81	Kept
	16	Postal / zip code	3.93	78.6	Kept
	17	Phone number	3.88	77.6	Kept
	18	Fax no	1.8	36	Removed
Identified numbers	19	National ID	4.2	84	Kept
	20	Visit number	3.98	79.6	Kept
	21	Medical record number	2.5	50	Removed
	22	Social security number	3.9	78	Kept
	23	Physician ID	3.96	79.2	Kept
	24	Specimen ID	2.8	56	Removed
	25	Hospital ID	2.2	44	Removed
	26	Report ID	1.8	36	Removed
	27	Insurance ID	1.88	37.6	Removed
	28	Family ID	1.6	32	Removed

are presented in Tables 2 and 3.

The experts participated in 2 rounds by completing the questionnaire.

At the end of the first Delphi round, 18 data elements were deleted (< 50%), 45 moved to the next round (50%-75%), and 24 marked as definitive (75% <). In addition,

Table 3. Ctd

Data classes	No	Data elements	Mean	Percentage	Final decision
Patient disposition	29	Admission date	4.35	87	Kept
	30	Reason for admission	4.20	84	Kept
	31	Type of admission	4.09	81.8	Kept
	32	Readmission	4.22	84.4	Kept
	33	Length of stay	4.1	82	Kept
	34	Discharge date	4.3	86	Kept
	35	Discharge status	4.3	86	Kept
	36	Underlying cause of death	4.1	82	Kept
	37	Date of death	4.05	81	Kept
	38	Discharge location	3.8	76	Kept
	39	Discharge recommendations	2.4	48	Removed
	40	Discharge /referral date	2.15	43	Removed
	41	Discharge /referral type	1.95	39	Removed
	42	Discharge Prescribed drugs	4.1	82	Kept
43	Date of follow-up	4.23	84.6	Kept	

Table 3. Ctd

Data Classes	No	Data elements	Mean	Percentage	Final Decision
Diagnostic	1	Disease history	4.8	96	Kept
	2	Comorbidity	4.6	92	Kept
	3	Family history	2.8	56	Removed
	4	Disease status	4.2	84	Kept
	5	Disease severity status	4.25	85	Kept
	6	Mental condition	2.2	44	Removed
	7	Case classification	4	80	Kept
	8	Vital sign	2.4	48	Kept
	9	Sing and symptoms	4.65	93	Kept
	10	symptoms types (if symptomatic)	4.6	92	Kept
	11	Symptom onset date	3.01	60.2	Removed
	12	Chief complaint	3.03	60.6	Removed
	13	Days from exposure to symptom onset	3.85	77	Kept
	14	Time between diagnosis and treatment	3.93	78.6	Kept
	15	Date of diagnosis	4.45	89	Kept
Exposure	16	Exposed to high risk agent	4.1	82	Kept
	17	Exposure type	2.85	57	Removed
	18	Cause of exposure	2.3	46	Removed
	19	Exposure history	4.78	95.6	Kept
	20	Activity on exposure	1.07	21.4	Removed
	21	Location of exposure	2.63	52.6	Removed
	22	Number of exposures	2.1	42	Removed
	23	Date of exposure	4.5	90	Kept
Physical Examination	24	Respiratory rate: per minute	4.4	85	Kept
	25	Pulse	2.6	52	Removed
	26	Waist circumference	2.7	54	Removed
	27	Temperature: °C	4.5	90	Kept
	28	Brachial Index	2.4	48	Removed
	29	Blood group	3.90	78	Kept
	30	Body Mass Index	3.05	61	Removed
	31	Blood pressure: mmHg	4	80	Kept
	32	Lung examination	4.15	83	Kept
	33	Heart rate: bit per minute	3.9	78	Kept
	35	Weight /height	1.8		Removed
Procedures	36	Quarantine / isolation	2.1	42	Removed
	37	Oxygen support	4.45	89	Kept
	38	Immunization/ vaccination	2.3	46	Removed
	39	Radiology	4.8	96	Kept
	40	CT features	4.95	99	Kept
	41	Lung segment involvement	4.5	90	Kept
	42	Prescription / medication	3.2	64	Removed
	43	LAB test name	4.9	98	Kept
	44	Test result	4.9	98	Kept
	44	Test time	3.89	77.8	Kept

no new data elements were suggested by the experts. After the second round, in general, 13 data elements for the nonclinical and 18 elements for the clinical category were excluded from the report template. Therefore, the experts agreed on 30 data elements from 43 data elements of the nonclinical category. The second category was the clinical data involving 4 data classes with 26 data elements. The ultimate data elements for the nonclinical and clinical categories were 30 and 26, respectively (Table 2). The results of weighing of data elements after the second round of Delphi are displayed in Table 3.

In Table 4, data classes, elements, and their formats and standard contents (recording template) were defined for 2 nonclinical and clinical data categories.

### The COVID-19 registry framework

In the development of the software, our focus was on accessibility and user-friendliness of the system to expe-

dite reporting time. Our designed system uses an advanced search capability to enable custom search, contact to site administrator, provide useful news about disease (prevention, self-care, treatment information, etc.), rendering daily statistics and multimedia instructions. Access to the registry is provided to registered members on the system home page (user name & password boxes)- Each user has a unique identification password and username to log into the system. Figures 1 and 2 display the designed web-based registry screen of COVID-19.


### Discussion

The lesson learned from previous global pandemics and the widespread prevalence of zoonotic viral diseases (eg, SARS and MERS), highlights the importance of patient registries in the field of new emerging outbreaks such as COVID-19 (34, 35). In this regard, for proper implementation of a public health surveillance system (PHSs), clini-

Table 4. Nonclinical and clinical MDS description for COVID-19 registry system

Administrative data category			Clinical data category		
Data elements	Content definition	Data Format	Data elements	Content definition	Data Format
Sociodemographic			Diagnostic		
Patient's name	First / middle / last name	String	Disease history	Free text	String
Father's name	First / middle / last name	String	Comorbidity	Free text	String
Age (in years)	*Infant: x<1y, *child: 1y<x<5y, *teenage: 5y<x<17y, *young: 17y<x<34y, *middle age: 34y<x<65y, *aged: x>65y	Categorical	Disease status	*Active, *inactive, *recovered	Categorical
			Disease severity status	*General, *severe, *critical	Categorical
Sex	*M *F	Categorical	Case classification	*Final, *suspicious *probable	Categorical
Date of birth	yyyy /mm/ dd	Date	Sing and symptoms	*Symptomatic, *a symptomatic	Binary
Place of birth	Geographical location: province, city, village	Categorical	symptoms types (if symptomatic)	Free text	String
Marital status	*Single *married *widowed, *other	Categorical	Days from exposure to symptom onset	Number of days	Integer
Employment status	*Unemployed, *employed, *retired, *student, *other	Categorical	Time between diagnosis to treatment	number of days	Integer
Occupation	Free text	String	Date of diagnosis	yyyy /mm/ dd	Date
			Exposure		
Race/ nationality	Iranian: *Persian, *Kurdish, *Turkish, *other	Categorical	Exposed to high risk agent	*Yes, *no, *unknown	Categorical
Educational level	*Illiterate, * less than high school diploma, *diploma, * bachelor, *master of science or above, *unspecified	Categorical	Exposure history	*Person-to-person * Animal-to-person * Contact with contaminated surfaces * Food/water born * Other, * unknown	Categorical
			Date of exposure	yyyy /mm/ dd	Date
			Physical Examination		
Home address	Province-city-street-alley- house no	String	Respiratory rate: per mi- nute	* ≤ 24 breaths per min * >24 breaths per min	Categorical
Postal / zip code	Ten digits with dash	Integer	Temperature: °C	* <37.3, *37.3 – 38, *38.1 – 39, * >39.0	Categorical
Phone number	Ten digits with +98 Identifier	Integer	Heart rate: bit per minute	* <60, *between 60-100, * >100, *unknown	Categorical
National ID	Validated numerical range	Integer	Blood group	RH positive: A, B, AB, O RH negative: A, B, AB, O	Categorical
Visit number	Validated numerical range	Integer	Blood pressure: mmHg	* <120, *between 120-129, *between 130-139, * >140, *unknown	Categorical
Social security number	Validated numerical range	Integer	Lung examination	*Clear/normal, *rales, *decreased breath sounds, *rhonchi, *wheezing	Categorical
Physician ID	Validated numerical range	Integer			





Home Search Contact Login News Sociodemographic

**Required data elements:**

First name:

Last name:

Father name:

Age(in years):

National ID:

Sex:  Male  female

Place of birth:

Marital status:

Marital status:  single  married


Employment status :

Home Address :

Postal / Zip code :

Reason for admission :

Fig. 1. Administrative data entry screen



Home Search Contact Login News Diagnostic

**Required data elements:**

**Disease history:**

Cardiovascular  Diabetes  Hypertension  Cancer  Respiratory  Liver  
 Nervous system  Urinary  Gastrointestinal  Endocrine  Musculoskeletal  Other

**Comorbidity:**

Hypertension  
 Diabetes  
 Cardiovascular  
 Cerebrovascular  
 Malignancy  
 HIV infection  
 Other

**Disease status:**  Active  Inactive  Recovered

**Disease severity status:**

**Case classification:**  Final  Suspicious  Probable

**Date of exposure:**

**Date of diagnosis:**

**Physical examination**

**Blood group:**  A  B  AB  O

**Respiratory rate(per minute):**  ≤ 24 breaths per min  Inactive  > 24 breaths per min

**Temperature(°C) :**

Fig. 2. Clinical data entry screen

tiveness, and support the decision-making and evidence-based design process (43).

The quality of clinical registers can be restricted due to poor uptake or unreliable data entry process. The manual data entry is time-consuming for clinical staff and is vulnerable to documentation errors, such as inaccuracies and omissions (9, 44). In COVID-19 registry, an electronic web-based data entry is provided to automatically reject incorrect values or those that are outside the range; furthermore, the manual entry of data is avoided as much as

possible.

Furthermore, to comply with other data quality criteria, such as data consistency and comparability in COVID-19 registry, first, most required data elements and their values were determined for reporting COVID-19 in a consistent manner across Iran's health system. COVID-19 registry is comprehensive and can provide an in-depth description of specific patient cohorts rather than delivering epidemiological data. Another key feature for any registry is interoperability with other health information systems that

can be helpful to avoid duplication of data entry and reduce the workload on care givers. Bergin et al (2016) also recognized some possible challenges in developing a registry that hinder comprehensive and accurate data capture, including the increased workload of health care providers and proper integration of data capture into daily clinical workflow (45). Therefore, it is valuable to harmonize data elements, data descriptions, and process for uniform capturing of each item (46, 47). Thus, in this study, both COVID19 MDS and detailed categories (levels) and data formats for data capturing were defined. For future studies, working on technical aspects of data exchanging to automated pool data in the registry is the next challenge.

Given some unfamiliar aspects of the COVID-19, further development and adjustments are required; thus, conducting a pilot study, including a further Delphi step to refine the MDS, is recommended. Moreover, this MDS may need to be evaluated from the perspectives of larger group of medical and public health experts to be applicable at the national level. Further, we used the Delphi consensus approach to reach an agreement on COVID-19 MDS. This technique has been demonstrated to be suitable for assessment information systems requirements (48). However, one of its restrictions is that most views are marginalized. Despite the aforementioned limitations, this registry provides a standardized and agreed dataset on COVID-19 to accumulate patients, so gradually larger cohorts will be available in the future. In addition, this registry can collect large volumes of data from multiple settings and lay the foundation to conduct in-depth analyses by the artificial intelligence (AI) technique on many unfamiliar aspects of COVID-19. In addition, it is expected to push quickly towards better scientific collaboration for COVID-19. Registry implementation also allowed us to evaluate the quality of care and to help inform best practice in controlling COVID-19.

### Conclusion

This study represents a fundamental effort towards building a national registry that uses information management approaches to improve accuracy, completeness, comparability, and interoperability of data about COVID-19 across the health care sector. This registry helps to conduct surveys to study various aspects of COVID 19 using a set of variables that were included in the registry according to the experts' opinions.

### Acknowledgments

This article is extracted from a research project supported by Ilam University of Medical Sciences (IR.MEDILAM.REC.1399.040). We also thank the Research Deputy of Ilam University of Medical Sciences for financially supporting this project.

### Conflict of Interests

The authors declare that they have no competing interests.

### References

1. Lin X, Gong Z, Xiao Z, Xiong J, Fan B, Liu J. Novel coronavirus

2. pneumonia outbreak in 2019: computed tomographic findings in two cases. *Korean J Radiol.* 2020;21(3):365-8.
3. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis.* 2020.
4. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. *J Infect.* 2020.
5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med.* 2020.
6. Alonso-Pérez J, Segovia S, Domínguez-González C, Olivé M, Grimón MDM, Fernández-Torrón R, et al. Spanish Pompe registry: baseline characteristics of first 49 patients with adult onset of Pompe disease. *Med Clin (Barc).* 2020.
7. Hornik CP, Gelfand AA, Szperka CL, Pezzuto T, Utevsky A, Kessel S, et al. Development of a Prospective Real-World Data Clinical Registry of Children and Adolescents With Migraine. *Headache.* 2020;60(2):405-15.
8. Bellgard MI, Render L, Radochonski M, Hunter A. Second generation registry framework. *Source Code Biol Med.* 2014;9(1):14.
9. Boulanger V, Schlemmer M, Rossvo S, Seebald A, Gavin P. Establishing Patient Registries for Rare Diseases: Rationale and Challenges. *Pharmaceut Med.* 2020:1-6.
10. Yang M, Loeb DF, Sprowell AJ, Trinkley KE. Design and implementation of a depression registry for primary care. *Am J Med Qual.* 2019;34(1):59-66.
11. Hurvitz EA, Gross PH, Gannotti ME, Bailes AF, Horn SD. Registry-based Research in Cerebral Palsy: The Cerebral Palsy Research Network. *Phys Med Rehabil Clin N Am.* 2020;31(1):185-94.
12. Irie H, Okamoto H, Uchino S, Endo H, Uchida M, Kawasaki T, et al. The Japanese Intensive care PATient Database (JIPAD): A national intensive care unit registry in Japan. *J Crit Care.* 2020;55:86-94.
13. Kazemi-Arpanahi H, Vashghani-Farahani A, Baradaran A, Mohammadzadeh N, Ghazisaeedi M. Developing a Minimum Data Set (MDS) for Cardiac Electronic Implantable Devices Implantation. *Acta Inform Med.* 2018;26(3):164-8.
14. Kazemi-Arpanahi H, Vashghani-Farahani A, Baradaran A, Ghazisaeedi M, Mohammadzadeh N, Bostan H. Development of a minimum data set for cardiac electrophysiology study ablation. *J Educ Health Promot.* 2019;8:101-.
15. Chang TH, Wu JL, Chang LY. Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis. *J Formos Med Assoc.* 2020.
16. Fang Z, Yi F, Wu K, Lai K, Sun X, Zhong N, et al. Clinical Characteristics of 2019 Coronavirus Pneumonia (COVID-19): An Updated Systematic Review. *medRxiv.* 2020.
17. Fu H, Xu H, Zhang N, Xu H, Li Z, Chen H, et al. Association between Clinical, Laboratory and CT Characteristics and RT-PCR Results in the Follow-up of COVID-19 patients. *medRxiv.* 2020.
18. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. *J Infect.* 2020.
19. Huang Y, Zhou H, Yang R, Xu Y, Feng X, Gong P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. *medRxiv.* 2020.
20. Jia J, Hu X, Yang F, Song X, Dong L, Zhang J, et al. Epidemiological characteristics on the clustering nature of COVID-19 in Qingdao City, 2020: a descriptive analysis. *Disaster Med Public Health Prep.* 2020:1-17.
21. Sahin AR, Erdogan A, Agaoglu PM, Dineri Y, Cakirci AY, Senel ME, et al. 2019 novel coronavirus (COVID-19) outbreak: a review of the current literature. *EJMO.* 2020;4(1):1-7.
22. Lyu P, Liu X, Zhang R, Shi L, Gao J. The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics. *Invest Radiol.* 2020.
23. Mao Y, Lin W, Wen J, Chen G. Clinical and pathological characteristics of 2019 novel coronavirus disease (COVID-19): a systematic reviews. *MedRxiv.* 2020.
24. Pormohammad A, Ghorbani S, Baradaran B, Khatam A, Turner R, Mansournia MA, et al. Clinical Characteristics, Laboratory Findings, Radiographic Signs and Outcomes of 52,251 Patients with Confirmed

- COVID-19 Infection: A Systematic Review and Meta-Analysis. Preprints. 2020.
24. Surveillances V. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. *China CDC Wkly.* 2020;2(8):113-22.
  25. Tabata S, Imai K, Kawano S, Ikeda M, Kodama T, Miyoshi K, et al. The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the outbreak on board the Diamond Princess cruise ship in Japan. *medRxiv.* 2020.
  26. Wang L, Duan Y, Zhang W, Liang J, Xu J, Zhang Y, et al. Epidemiologic and Clinical Characteristics of 26 Cases of COVID-19 Arising from Patient-to-Patient Transmission in Liaocheng, China. *Clin Epidemiol.* 2020;12:387.
  27. Wang X, Fang J, Zhu Y, Chen L, Ding F, Zhou R, et al. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. *Clin Microbiol Infect.* 2020.
  28. Xia XY, Wu J, Liu HL, Xia H, Jia B, Huang WX. Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19. *J Clin Virol.* 2020:104360.
  29. Zhao X, Zhang B, Li P, Ma C, Gu J, Hou P, et al. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. *medRxiv.* 2020.
  30. Zheng Y, Xu H, Yang M, Zeng Y, Chen H, Liu R, et al. Epidemiological Characteristics and Clinical Features of 32 Critical and 67 Noncritical Cases of COVID-19 in Chengdu. *J Clin Virol.* 2020:104366.
  31. Šimović V, Varga M. Applying SQL database query to access SQL server 2019—visual studio 2019. *J Agron.* 2019;6.
  32. Strauss D. Being More Productive in Visual Studio. Exploring Advanced Features in C#: Springer; 2019. p. 221-81.
  33. Petrovečki M, Kovačević Ž. Featured characteristics of SQL Server 2019. *Polytechnic Design.* 2019;7(1):1-7.
  34. Allam Z, Jones DS, editors. On the coronavirus (COVID-19) outbreak and the smart city network: universal data sharing standards coupled with artificial intelligence (AI) to benefit urban health monitoring and management. *Healthcare*; 2020: Multidisciplinary Digital Publishing Institute.
  35. Fisher D, Heymann D. Q&A: The novel coronavirus outbreak causing COVID-19. *BMC Med.* 2020;18(1):1-3.
  36. Choinière M, Ware M, Pagé M, Lacasse A, Lanctôt H, Beaudet N, et al. Development and implementation of a registry of patients attending multidisciplinary pain treatment clinics: The Quebec Pain Registry. *Pain Res Manag.* 2017;2017.
  37. Akand M, Sarıca K, Kiremit MC, Soytas M, Güven S. Development of a prospective data registry system for retrograde intrarenal surgery in renal stones: Turkish Academy of Urology Prospective Study Group (ACUP study). *Turk J Urol.* 2020;46(1):57.
  38. Hoque DME, Kumari V, Hoque M, Ruseckaite R, Romero L, Evans SM. Impact of clinical registries on quality of patient care and clinical outcomes: a systematic review. *PLoS One.* 2017;12(9):e0183667.
  39. Golan R, Bernstein A, Sedrakyan A, Daskivich TJ, Du DT, Ehdai B, et al. Development of a nationally representative coordinated registry network for prostate ablation technologies. *J Urol.* 2018;199(6):1488-93.
  40. Shanbehzadeh M, Ahmadi M. Identification of the necessary data elements to report AIDS: A systematic review. *E-physician.* 2017;9(12):5920.
  41. Ieva F, Gale CP, Sharples LD. Contemporary roles of registries in clinical cardiology: when do we need randomized trials? *Taylor & Francis*; 2014.
  42. Tian Q, Liu M, Min L, An J, Lu X, Duan H. An automated data verification approach for improving data quality in a clinical registry. *Comput Methods Programs Biomed.* 2019;181:104840.
  43. Korngut L, Genge A, Johnston M, Benstead T, Bourque P, Briemberg H, et al. Establishing a Canadian registry of patients with amyotrophic lateral sclerosis. *Can J Neurol Sci.* 2013;40(1):29-35.
  44. Williams A, Goedicke W, Tissera KA, Mankarious LA. Leveraging Existing Tools in Electronic Health Record Systems to Automate Clinical Registry Compilation. *Otolaryngol Head Neck Surg.* 2020;162(3):408-9.
  45. Bergin K, Moore E, McQuilten Z, Wood E, Augustson B, Blacklock H, et al. Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. *BMC.* 2016;16(1):151.
  46. Plotnicki L, Kohl C, Höcker B, Krupka K, Rahmel A, Pape L, et al., editors. The CERTAIN Registry: a novel, web-based registry and research platform for pediatric renal transplantation in Europe. *Transplantation proceedings*; 2013: Elsevier.
  47. Gerke AK, Tang F, Cozier YC, Lash MT, Schappet J, Phillips E, et al. A web-based registry for patients with sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis.* 2017;34(1):26-34.
  48. Niazkhani Z, Cheshmekaboodi M, Pirnejad H, Makhdoomi K, Nikibakhsh AA, Abkhiz S, et al. Enabling informed policymaking for chronic kidney disease with a registry: Initiatory steps in Iran and the path forward. *Health Policy Technol.* 2018;7(1):73-80.